Phaseline

Companies › OPKO Health

OPKO Health: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Other, Metabolic and endocrine; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Calcifediol (CTAP101)
Vitamin D receptor agonist
VDRPhase 2CKD Stage 3Oct 2027
OPK-88006
unclear - MASH therapeutic, mechanism not specified in registry
–Phase 1MASHDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07494045Calcifediol (CTAP101)Phase 2CKD Stage 3Metabolic and endocrineOct 2027
NCT07512427OPK-88006Phase 1MASHOtherDec 2027

From the company's SEC filings

Cash of $384m on 2026-09-30; operating cash outflow about $133m a year; runway about 35 months at that burn, to Aug 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

VDR (1)

Companies with the same targets

RDC Clinical

Companies built like this

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) BrightGene Bio-Medical Technology Eloxx Pharmaceuticals Kylonova (Xiamen) Biopharma Energenesis Biomedical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.